Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00979732 · ClinicalTrials.gov registry record · NA
The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension
A NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT00979732: Completed NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
NCT00979732 is a NA study that has completed, run by Clinical Nutrition Research Center, Illinois Institute of Technology. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00979732, a NA study, has completed, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
In this research study, the investigators are interested in learning how extracts from grape seeds can help those individuals with high blood pressure. The investigators also hope to learn how grape seed extract effects your blood and cell functions. The grape seed extract the investigators will use in the study will be provided either in a beverage or a capsule form and is currently available on the market. This study is also using a placebo; therefore the treatment subjects receive may or may not contain the grape seed extract. The purpose of this study is to determine if the grape seed extract (GSE) will lower blood pressure in people with slightly high blood pressure (Pre-Hypertension).
Primary Outcome
BP was monitored using ambulatory BP monitors (Ambulo2400; Tiba Medical, Inc.) that were programmed to take BP measurements automatically at 1-h intervals for a period of 24 h. BP measurements were scheduled at week 0 and 6 of the intervention (for efficacy assessment). Day-time BP and night-time BP were divided based on the subject's sleeping hours and hours awake.
Interventions
- DIETARY_SUPPLEMENT grape seed extract
- DIETARY_SUPPLEMENT grape seed extract placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-11-15 |
| Est. Completion | 2014-10-15 |
| Phase | NA |
What the finished NCT00979732 record still lists
NCT00979732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which grape seed extract is the first listed.
NCT00979732 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00979732 about?
NCT00979732 is a clinical study titled "The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension". In this research study, the investigators are interested in learning how extracts from grape seeds can help those individuals with high blood pressure. The investigators also hope to learn how grape seed extract effects your blood and cell functions. The grape seed extract the investigators will us...
What is the current status of trial NCT00979732?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2009-11-15. Estimated completion is 2014-10-15.
What interventions are being tested in trial NCT00979732?
The interventions under investigation include: grape seed extract (DIETARY_SUPPLEMENT), grape seed extract placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00979732?
This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00979732's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI